| Literature DB >> 26046755 |
Abstract
Stimulating an endogenous regenerative response is a powerful approach for potential treatment of chronic demyelinating diseases such as multiple sclerosis. Recently in Nature, Najm et al. (2015) identified two clinically relevant, FDA-approved compounds that promote oligodendrocyte progenitor cell differentiation and induce remyelination in demyelinating disease models.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26046755 DOI： 10.1016/j.stem.2015.05.010
Source DB: PubMed Journal: Cell Stem Cell ISSN： 1875-9777 Impact factor: 24.633